Overview

NeuroEM Therapeutics was founded in January, 2013 (Delaware C-Corp.) as a clinical-stage medical device research and development company located in Phoenix, Arizona.

NeuroEM Therapeutics is developing and plans to market a self-contained head device that, if clinically successful, will provide “in home” electromagnetic treatment to the brains of Alzheimer’s patients. While providing treatment for 1-2 hours per day, the head device will not hinder daily activities. We believe the device will directly attack the Alzheimer’s Disease process. It would be available through neurologists and other health professions who diagnosis memory disorders.

Management

NeuroEM Therapeutics CEO, Dr. Gary Arendash, is handling managerial and scientific responsibilities until the company’s Board of Directors is formed. He has extensive contacts within medicine (especially Alzheimer’s Disease), research, development & regulatory compliance.

  • GARY. W. ARENDASH, PH.D.
    CEO and President

    Dr. Arendash was a Full Professor and Research Professor at the University of South Florida for 30 years. During the last 6 years there, he directed the Florida Alzheimer’s Disease Research Center’s Animal Core. Dr. Arendash’s research expertise involves development of therapeutics against Alzheimer’s Disease. He has published over 100 peer-reviewed articles in first tier journals, including Science, Nature and the Journal of Alzheimer’s Disease – the last of which he has held the position of Senior Editor. During his academic career at USF, Dr. Arendash was awarded over $4.7 million in research support from extramural granting agencies, including the National Institutes of Health (NIH), the Alzheimer’s Disease and Related Disease Association (ADRDA), and the United Parkinson’s Association. Dr. Arendash was among the very first to provide evidence that Alzheimer’s Disease starts in the brain decades before it is diagnosed. As well, he and his colleagues published initial evidence that immunotherapy was a viable approach to AD. Publication of Dr. Arendash’s landmark study in 2010 providing the first evidence that electromagnetic treatment provides cognitive benefit to Alzheimer’s mice resulted in worldwide interest from the news media. At NeuroEM Therapeutics, Dr. Arendash is handing managerial and scientific responsibilities until the company’s Board of Directors is formed. He received his Ph.D in Neuroscience/Physiology at the University of California, San Francisco (UCSF). Dr. Arendash then did his post-doctoral research at UCLA’s Brain Research Institute prior to joining the faculty at the University of South Florida.

Collaborators, Partners, and Consultants

Medical Device Development

  • Left Coast Engineering

    Rob Baranowski,
    Senior Engineering Project Lead

  • Ocotillo Electromagnetics:

    David Wittwer, Ph.D.
    Richard Ziolkowski, Ph.D.

  • Remarkable Technologies

    Eric Knight, President

LEGAL, REGULATORY, AND COMPLIANCE

  • Jennings, Strouss & Salmon, P.L.C.

    Richard Lieberman, Chairman,
    Corporate, Securities & Finance Dept.

    Michael Kelly, Chairman,
    Intellectual Property Group

  • KRS Inc.

    Debbie Koeneman

Clinical Trials

  • Byrd Alzheimer’s Institute

    Amanda Smith MD
    Jill Smith, MA, CCRC

  • University of South Florida College of Pharmacy

    Chuanhai Cao, Ph.D.

Sbir Research

  • Arizona State University

    Mike Sierks, Ph.D., ASU School of Engineering

    James Aberle, Ph.D., ASU School of Electrical Engineering

    Jeff Yarger, Ph.D., ASU Magnetic Resonance Research Center

    Greg Holland, Ph.D., ASU Dept. of Chemistry and Biochemistry

    Wade Van Horn, Ph.D., ASU Dept. of Chemistry and Biochemistry

Scientific Advisory Board

Huntington Potter, Ph.D.

Dr. Huntington Potter is Professor of Neurology, member of the Linda Crnic Center for Down Syndrome, and Director of the Rocky Mountain Alzheimer’s Disease Center at the University of Colorado Anschutz Medical Campus. He is devoted to studying the mechanistic relationship between Alzheimer’s Disease and Downs syndrome, recognizing that these disorders are two sides of the same coin.  Prior to joining UC Denver, Dr. Potter studied, researched and taught for 30 years at Harvard University. He received his AB Cum Laude in Physics and Chemistry and his MA and PhD in Biochemistry and Molecular Biology before spending 13 years on the faculty of the Neurobiology Department. In 1998, Dr. Potter joined the Faculty at the University of South Florida as the Eric Pfeiffer Chair for Research on Alzheimer’s Disease. He designed and directed the NIA-designated Florida Alzheimer’s Disease Research Center at USF and from 2004-2008 he was CEO of the Johnnie B. Byrd Sr. Alzheimer’s Center & Research Institute  during this time, the Institute built the largest free-standing Alzheimer’s disease research institute in the world.  Dr. Potter discovered that Alzheimer’s disease and Down syndrome, which invariably leads to Alzheimer’s by age 30-40, are mechanistically related to each other through the development of cells with abnormal numbers of chromosomes; this is the focus of his current research at UC Denver. He is author of over 100 scientific articles/books and is the holder of 15 U.S. and foreign patents.  In 2010, Dr. Potter was elected a Fellow of the American Association for the Advancement of Science and was selected one of Colorado’s Top Thinkers of 2013 by the Denver Post.  His electron micrographs of DNA are on permanent exhibit in the National American History Museum of the Smithsonian Institute in Washington D.C.

Richard Caselli, M.D.

Dr. Caselli is Associate Director and Clinical Core Director of the Alzheimer’s Disease Center at Mayo Clinic in Arizona, which focuses on symptomatic patients with mild cognitive impairment and dementia.  He is also a Professor of Neurology at Mayo Clinic’s College of Medicine.  Dr. Caselli has served at Mayo’s Scottsdale campus since 1990 and is also recent Past Chairman of Mayo’s Department of Neurology.  He holds an adjunct clinical faculty appointment at the Biodesign Institute at Arizona State University, serves as an Adjunct Professor at ASU’s Department of Biomedical Informatics, and currently is a Member of the Advisory Board of the Center for Services Leadership of the W.P. Carey School of Business at ASU.  Dr. Caselli also serves on the board of directors of the Arizona Alzheimer’s Consortium.  He is certified by the American Board of Electrodiagnostic Medicine, American Board of Neurology and Psychiatry, and National Board of Medical Examiners. Dr. Caselli received both his M.D. and bachelor’s degrees from Columbia University in New York.  He served an internship and residency at Mayo Graduate School of Medicine and a fellowship in behavioral neurology and cognitive neuroscience at the University of Iowa College of Medicine.  The research program of Dr. Caselli focuses on cognitive aging and the changes that can be detected before the symptomatic onset of memory loss and related symptoms of Alzheimer’s disease.  His personal focus is on the neuropsychological and related behavioral changes in AD that can be detected.  Through a close series of collaborations, he is also involved in brain imaging (FDG-PET, PIB-PET and MRI), neuropathology, genomics, and epigenetic factors that influence Alzheimer’s disease risk and age of onset.

Ranjan Duara, M.D.

Dr. Duara is the Medical Director of the Wien Center for Alzheimer’s Disease and Memory Disorders at Mount Sinai Medical Center. He is also Associate Director of the University of Florida/Mt. Sinai Alzheimer’s Disease Research Center, and director of its clinical core based at Mount Sinai.  Through his work as co-director and clinical core leader of the Florida Alzheimer’s Disease Research Center and principal investigator of the Alzheimer’s Disease Initiative’s Florida Brain Bank, Dr. Duara has helped to enhance what is known about the biology of the disease. In May 2005, Dr Duara and his team, in collaboration with the Johnnie Byrd Alzheimer’s Institute at the University of South Florida in Tampa, received a prestigious grant from the National Institutes of Health (NIH) to become one of 31 Alzheimer’s Disease Research Centers (ADRC) in the U.S to conduct cutting-edge research on Alzheimer’s. Dr. Duara is an Associate Professor of Medicine, Neurology and Psychiatry at the University of Miami School of Medicine.  He completed neurology residencies in the United Kingdom and at Thomas Jefferson University Hospital in Philadelphia, and did a fellowship in neuroscience and neuroimaging at the National Institutes of Health. His research has focused primarily on early diagnosis of Alzheimer’s disease and other dementias, neuroimaging, genetic epidemiology, and the methodology for staging the transition from normal cognitive aging to dementia. He has contributed to more than 150 articles in peer-review scientific journals and has been an investigator in numerous clinical trials of novel agents for the treatment of Alzheimer’s Disease. Dr. Duara is also the chair and organizer of the Mild Cognitive Impairment Symposium, which is held annually in Miami Beach.

George Perry, Ph.D.

Dr. Perry is recognized internationally for his work in the field of Alzheimer’s disease research, particularly in the area of oxidative stress. He has published over 500 peer-reviewed papers involving Alzheimer’s Disease, which is in the top 1% of Alzheimer’s researchers.  Dr. Perry’s work has been cited over 50,000 times and he is recognized as a Thompson-Reuters highly cited researcher. Dr. Perry is editor for numerous journals and is editor-in-chief for the Journal of Alzheimer’s Disease.  He is also Dean of the University of Texas College of Sciences at San Antonio.  Dr. Perry is a fellow of the American Association for the Advancement of Sciences, the Microscopy Society of America, past-president of the American Association of Neuropathologists, a member of the Dana Alliance for Brain Initiatives, and a Fulbright Specialist. He is a Foreign Correspondent Member of the Spanish Royal Academy of Sciences and the Academy of Science Lisbon.  Dr. Perry earned a B.A. in Zoology from the University of California, Santa Barbara and a Ph.D. in Marine Biology from the Scripps Institution of Oceanography. He received a postdoctoral fellowship in the Department of Cell Biology at Baylor College of Medicine. In 1982, he joined the faculty of Case Western Reserve University, where he currently holds an adjunct appointment.